1471-2164-9-624 1471-2164 Research article <p>Microarray-based approach identifies microRNAs and their target functional patterns in polycystic kidney disease</p> Pandey Priyanka priyankashahi2001@gmail.com Brors Benedikt b.brors@dkfz-heidelberg.de Srivastava K Prashant p.srivastava@dkfz.de Bott Andrea andrea.bott@medma.uni-heidelberg.de Boehn NE Susanne susanne_boehn@hotmail.com Groene Herrmann-Josef h.-j.groene@dkfz.de Gretz Norbert norbert.gretz@medma.uni-heidelberg.de

Medical Research Center, University Hospital Mannheim, D-68167 Mannheim, Germany

Department of Theoretical Bioinformatics, German Cancer Research Center, D-69120 Heidelberg, Germany

Department of Cellular and Molecular Pathology, German Cancer Research Center, D-69120 Heidelberg, Germany

 BMC Genomics 1471-2164 2008 9 1 624 http://www.biomedcentral.com/1471-2164/9/624 19102782 10.1186/1471-2164-9-624 11 9 2008 23 12 2008 23 12 2008 2008 Pandey et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background

MicroRNAs (miRNAs) play key roles in mammalian gene expression and several cellular processes, including differentiation, development, apoptosis and cancer pathomechanisms. Recently the biological importance of primary cilia has been recognized in a number of human genetic diseases. Numerous disorders are related to cilia dysfunction, including polycystic kidney disease (PKD). Although involvement of certain genes and transcriptional networks in PKD development has been shown, not much is known how they are regulated molecularly.

Results

Given the emerging role of miRNAs in gene expression, we explored the possibilities of miRNA-based regulations in PKD. Here, we analyzed the simultaneous expression changes of miRNAs and mRNAs by microarrays. 935 genes, classified into 24 functional categories, were differentially regulated between PKD and control animals. In parallel, 30 miRNAs were differentially regulated in PKD rats: our results suggest that several miRNAs might be involved in regulating genetic switches in PKD. Furthermore, we describe some newly detected miRNAs, miR-31 and miR-217, in the kidney which have not been reported previously. We determine functionally related gene sets, or pathways to reveal the functional correlation between differentially expressed mRNAs and miRNAs.

Conclusion

We find that the functional patterns of predicted miRNA targets and differentially expressed mRNAs are similar. Our results suggest an important role of miRNAs in specific pathways underlying PKD.

Background

MicroRNAs (miRNAs) are known to regulate the expression of key genes relevant to cancer and potentially other diseases 123. MiRNAs are short noncoding RNAs of about 22 nt length that have recently been shown to play important roles in mammalian gene expression 1345. They induce posttranscriptional gene repression by blocking protein translation (by binding to the 3' UTR of their target genes) or by inducing mRNA degradation, and have the potential to play central roles in physiological and pathological conditions. Recently, it has been shown that miRNAs can also increase translation 67. The physiological conditions of a cell seem to affect the recruitment of regulatory proteins, which can alter the effect of a miRNA.

MiRNAs are transcribed as long primary transcripts (pri-miRNAs), some of them being polycistronic, which are processed in the cell nucleus by an enzyme called Drosha, yielding precursor miRNAs (pre-miRNAs) that exhibit a characteristic stem-loop sequence 8. These are exported into the cytosol where mature miRNAs are generated by the RNAse Dicer, producing the small single-stranded miRNA 8. Translational inhibition, which seems to be the major mode of action in animals, is performed by a riboprotein complex called RNA-induced silencing complex (RISC) consisting of the miRNA and proteins of the argonaute family 910.

MiRNAs are involved in several cellular processes, including cellular differentiation 1112, organism development 1314, and apoptosis 1516. While all of these are conserved in metazoans, the number of conserved miRNAs between mammals suggests that there are additional functions only found in vertebrates 4, e.g. controlling hematopoietic differentiation 17. Recent studies provide growing evidence for the involvement of miRNAs in cancer pathomechanisms 18192021. However, to date nothing is known regarding miRNAs in the context of Polycystic Kidney Diseases.

Cilia and flagella are ancient, evolutionary conserved organelles that project from cell surfaces to perform diverse biological roles, including whole-cell locomotion, movement of fluid, chemo-, mechano-, and photosensation, and sexual reproduction. The concept of ciliopathies has helped in advancing a unifying theory of cystic kidney diseases 22. This theory states that the products of all genes that are mutated in cystic kidney diseases in humans, mice, or zebrafish are expressed in primary cilia or centrosomes of renal epithelial cells 22.

There are numerous disorders linked to basal body and/or cilia dysfunction, including polycystic kidney disease (PKD), primary ciliary dyskinesia (PCD), nephronophthisis (NPHP1–9) 23, Senior-Loken syndrome, Joubert syndrome, Meckel syndrome, oral-facial-digital syndrome, Alström syndrome and Bardet-Biedl syndrome 24. These syndromes are typically associated with one or more of the symptoms like cystic kidneys 25, retinal degeneration and retinitis pigmentosa 16, situs inversus 2627, anosmia 28, respiratory problems 26, infertility 26, hydrocephalus 29, other ailments like obesity, diabetes, liver fibrosis, hypertension, heart malformations, skeletal anomalies (e.g. polydactyly), cognitive impairment and developmental defects such as exencephaly 1626.

Although the mechanisms of the cyst formation are not clearly understood, they are postulated to involve improper functioning of several pathways including cell proliferation, apoptosis, cell polarity, and fluid secretion 30. Woo 31 has described apoptotic cells in glomeruli, cyst walls, and in both cystic and non-cystic tubules of the polycystic kidneys. Apoptotic loss of renal tissue may be associated with the progressive deterioration of renal function that occurs in patients with autosomal dominant polycystic kidney disease (ADPKD). There is evidence that genes involved in the regulation of cell proliferation, such as p53, c-fos, cyclin D1, and c-myc may be involved in the control of apoptosis 32. Veis and colleagues have shown overexpression of c-myc in human ADPKD in association with increased levels of apoptosis and cell proliferation 33. It is clear that pathogenesis of PKD is very complicated and involves multiple molecular pathways with overlapping, complementary, or opposing effects. There are several signalling pathways that have been implicated in ciliary function 34. The dysregulation of mitogen-activated protein kinases (MAPKs) in the cyst epithelium of pcy (polycystic kidney disease) mice, carrying a missense mutation in NPHP3 35, is a downstream consequence of disturbed renal monocilia function 36. The proteins, implicated in the formation of renal cysts in tuberous sclerosis, have been found at the ciliary base. They form a complex that inhibits mTOR resulting in retarded cyst formation in rats with PKD 37. Cilia-mediated signalling acts as a switch between canonical and non-canonical Wnt signalling pathways 34.

Rats or mice have been used as common model systems for the study of PKD. The Hannover rat, Han:Sprague-Dawley (SPRD)-cy rat is an accepted model for human PKD 3839 and has been efficiently used since more than a decade. It is an autosomal dominant model for PKD resulting in cyst formation and slowly progressive chronic renal failure 39. In the current investigation, we explore the transcriptional changes that occur in PKD and investigate if these changes could be related to miRNAs. We use a microarray-based approach to profile the transcriptional (mRNA) changes as well as changes in the miRNA expression patterns in PKD. We use the Han:SPRD cy/+ rat model 39 for our current investigation. Our results suggest several miRNAs may be involved in regulating the genetic switches in PKD. Furthermore we describe some newly detected miRNAs in the kidney.

Methods

Animals and physiological state

Inbred homozygous unaffected (+/+) and heterozygous affected (cy/+) Han:SPRD rats exhibiting PKD were investigated. The Han:SPRD-cy rats used in this study carry a dominant mutation that causes cystic kidneys and is an accepted model for human PKD 40. After approximately 40 generations of inbreeding this substrain was registered as PKD/Mhm-cy inbred strain of rats: polycystic kidney diseases, Mannheim, Germany hereafter designated as PKD/Mhm. From each of the aforementioned PKD/Mhm (cy/+) and PKD/Mhm (+/+) animals, littermates were investigated. The animals were sacrificed by cervical dislocation at day 36. On the day of sacrifice, body weight was determined. Following dislocation, the left and right kidneys were immediately removed and weights were determined. Kidneys were preserved for histological analyses and the genotypes were confirmed. Histological analysis of pathogenesis was performed using hematoxylin-esosin (HE) staining of the kidney section (3 μm) followed by cyst grading under light microscope 4142; kidneys were graded on 1–5 scale as previously described 4142.

We had ethical approval to carry out this work on animals by Regierungspraesidium Nordbaden and Internal Review Board.

RNA isolation and Affymetrix microarray

Total RNA was extracted using TRIzol method according to manufacturer's protocol (Invitrogen Life Technologies). cDNA synthesis was performed using the SuperScript Choice System (Invitrogen Life Technologies, Invitrogen Corporation) according to manufacturer's protocol. Biotin-labelled cRNA was produced using ENZO BioArray High Yield RNA Transcript Labelling Kit. The standard protocol from Affymetrix (Santa Clara, CA) with 3.3 μL of cDNA was used for the in vitro transcription (IVT). Cleanup of the IVT product was done using CHROMA SPIN-100 columns (Clontech, USA). Spectrophotometric analysis was used for quantification of cRNA with acceptable A260/A280 ratio of 1.9 to 2.1. After that, the cRNA was fragmented using Affymetrix defined protocol. Labelled and fragmented cRNA was hybridized to Affymetrix Rat 230_2 microarrays for 16 hrs at 45°C using Affymetrix defined protocol. cRNA in the range of 15 μg was used for all the 12 microarrays. Microarrays were washed using an Affymetrix fluidics station 450 and stained initially with streptavidin/phycoerytherin. For each sample the signal was further enhanced by incubation with biotinylated goat anti-streptavidin followed by a second incubation with streptavidin/phycoerytherin, and a second round of intensities were measured. Microarrays were scanned with an Affymetrix scanner controlled by the Affymetrix Microarray Suite software. A total of 12 Affymetrix whole genome arrays (from 6 healthy and 6 diseased biological replicates) were performed.

MicroRNA microarray

Locked Nucleic Acid (LNA) based miRNA hybridization assays were done as described by Castoldi et al. 43. Briefly, 5 μg RNA was hybridized to a miRNA microarray (miChip v6.0), containing probes for ~300 miRNAs, based on LNA-modified and Tm-normalized oligonucleotide capture probes (miRCURY Array probes, Exiqon) spotted onto Codelink (GE Healthcare) in multiple replicates, and scanned using an Axon Scanner 4000B. Microarray images were analyzed using the Genepix Pro 4.0 software 43. As for the Affymetrix whole genome arrays, 6 biologically replicated arrays, each for healthy and diseased animals (total of 12 chips) were performed.

Statistical and bioinformatics analysis of microarray data

Microarray data obtained from Affymetrix chips were analyzed using SAS Micro-Array Solution version 1.3 (SAS, USA). Normalization of raw data was performed by fitting a mixed linear model across all arrays in the experiment. Log2-transformed scores of all spot measures were subjected to normalization. Identification of differentially expressed genes was carried out by Mixed Model Analysis (MMA) using ANOVA approach. A Bonferroni adjustment for multiple testing with α ≤ 0.05 was used to calculate the statistical significance threshold/cut-off [negative log10 (α)]. Custom CDFs version 8 (UniGene CDF files) 44 were used for annotations. Significantly up-regulated genes in PKD/Mhm (cy/+) animals were defined as those with >0 log-fold-changes in expression and down-regulated as those having <0 log-fold-changes in expression at p-value < 0.05 (adjusted for multiple testing).

The raw data from miRNA chips were also normalized and analyzed using the same modules in SAS Micro-Array Solution version 1.3, as described above. Significantly up-regulated miRNAs in PKD/Mhm (cy/+) animals were defined as those with >0 log-fold-changes in expression and down-regulated as those having <0 log-fold-changes in expression at p-value < 0.05 (adjusted for multiple testing).

Genes previously reported as targets for the significantly regulated miRNAs, and differentially regulated in PKD, were obtained from Argonaute 45. In addition, targets for the significantly regulated miRNAs, in the genes differentially regulated in PKD, were predicted using two algorithms: TargetScan 46 and miRanda 47. To identify the genes commonly predicted by both algorithms, results were intersected using a Perl script; the intersection of TargetScan and miRanda algorithms was used for further analysis.

Identification of pathways possibly affected by miRNAs and their target genes in PKD

The pathways affected in PKD were determined for the significantly regulated genes from KEGG 48, GeneOntology (GO) 49, Biocarta http://www.biocarta.com/ and the Molecular Signature database 50. To check whether significantly regulated genes are overrepresented in a pathway in PKD or not, Fisher's exact test 51 without correction for multiple testing was used. Pathways showing p-value less than 0.05 were considered as significantly enriched.

Reverse transcription and quantitative real-time PCR (qPCR) analysis of miRNAs

qPCR assays for miRNAs were performed using "TaqMan MicroRNA Assays" (Applied Biosystems, USA). The reverse transcriptase reactions were performed as per the manufacturer's protocol. Real-time PCR was also performed using a standard TaqMan PCR kit protocol on the Applied Biosystems 7000 Sequence Detection System. 6 biological replicates were used for analysis and all the reactions were run in quadruplicates. The comparative CT method for relative quantitation of gene expression was used to determine miRNA expression levels among the normal animals and PKD/Mhm (cy/+) animals according to manufacturer's protocol. miR-193a was used as an endogenous control to normalize the expression levels of targets. The miR-193a served as a good choice for endogenous control because its expression was almost uniform in all the samples on the miRNA-chips (0.99 ± 0.026) and it was not differentially regulated among the tested samples. miRNAs with ubiquitous and stable expression values are superior normalizers to other RNAs such as 5S rRNA, U6 snRNA or total RNA 5253. Consistency in expression of miR-193a across all the samples was evident in qPCR assays (mean CT-value 29.51 ± 0.19). The significance of differences in relative expression of miRNAs among the two groups was tested by One-way ANOVA method in SAS version 9.1.

Results

Pathological status of PKD/Mhm(cy/+) and healthy PKD/Mhm (+/+) animals

We used 36 day-old PKD/Mhm(cy/+) and control (healthy) PKD/Mhm (+/+) animals to profile expression differences in m- and mi-RNAs. At this time the disease is still in the early stages. The Cy/+ Han:SPRD rat develops clinically detectable PKD by 8 weeks of age as evidenced by a doubling of kidney size and kidney failure compared with +/+ control rats. But disease symptoms in form of cysts can be observed using histological sectioning of the kidneys. Using HE staining followed by cyst counting, diseased kidneys can be grouped into 5 grades 4142. Grade 1 kidneys have occasionally small and medium-sized cysts and sometimes small accumulations of predominantly small cysts in up to four localizations per slide. Grade 2 kidneys have few regularly distributed small and medium-sized cysts with up to five medium-sized cysts per visual field, rarely large cysts (considerably larger than the size of the glomeruli), and cysts are not detected in every visual field. Grade 3 kidneys have several small and medium-sized cysts (up to 10 medium-sized cysts per visual field), few large cysts and cysts are in any visual field. A great number of small, medium-sized and large cysts with two or more large cysts in nearly any visual field and the occurrence of net-like structures that linked large cysts together are the characteristics of grade 4. In grade 5 there is practically no normal kidney tissue visible and the histology exhibits only large cysts and network-like structures. Six biological replicates graded 3–4 (Figure 1).

<p>Figure 1</p>

Examples for different cyst gradings in 36 day old male PKD/Mhm rats

Examples for different cyst gradings in 36 day old male PKD/Mhm rats. At this age cyst grades of heterozygous (PKD/Mhm (cy/+)) affected kidneys are ranging between grade 3 (B) and 4(C), compared to a homozygous unaffected (healthy) kidney (A). Most of the animals are showing cyst grade 3. Hematoxylin/Eosin stained; Scale bar 250 μm.

In order to get insight into the genome-wide transcriptional rearrangements during PKD, we adapted a microarray based approach (Figure 2). We co-profiled the changes in transcript (mRNA) and miRNA expressions from the same sets of healthy and diseased kidney tissue using Affymetrix and Exiqon arrays for mRNA and miRNAs respectively.

<p>Figure 2</p>

Schematic representation of combinatorial approach identifying miRNAs and their targets

Schematic representation of combinatorial approach identifying miRNAs and their targets. mRNA and miRNA expression profilings were analysed by Mixed Model Analysis in SAS. 935 genes were differentially regulated on Affymetrix chips whereas 30 miRNAs were differentially changed on Exiqon chips. Target genes for differentially expressed miRNAs were obtained from Argonaute as well as TargetScan and miRanda and resulting genes were overlapped with differentially expressed mRNAs. Functionally related gene sets or pathways, determined for differentially expressed mRNAs and predicted target genes of differentially expressed miRNAs, were compared and the overlap gave 36 associated gene sets, out of which 10 were significantly enriched pathways.

Profiling miRNA expression change during PKD

In order to investigate the changes in miRNA profiles, we examined the expression of miRNAs between kidneys of PKD/Mhm (cy/+) and control PKD/Mhm (+/+) animals using LNA-based miRNA-chips 43. miRNAs are highly conserved between human, mouse and rat 54, therefore, above said chips could be effectively used to profile miRNA in our rat model. We identified 30 differentially regulated miRNAs (Table 1), distributed in 21 different families, at a cut-off ≥ 1.7 (negative log10 (p-value ≤ 0.05, after Bonferroni's correction for multiple testing)). Out of 30 miRNAs, 29 were down-regulated in PKD/Mhm (cy/+) animals and only one miRNA, miR-21, was up-regulated. Cluster analysis of chips showed that miRNA-microarray was able to distinguish 83.3% diseased and healthy animals (Figure 3). Interestingly, the expressions of miR-31 and miR-217 have not been previously reported in kidney. We verified the changes in the expression patterns of some of these miRNAs using quantitative real-time PCR (qPCR; Figure 4). We verified the expression changes of the only up-regulated miRNA, miR-21: in the qPCR assays, it was 3.5 fold up-regulated in the kidney of diseased animals, compared to healthy ones. In line with the expression on the miRNA-arrays, in qPCR analysis (Figure 4), miR-31 was 3.15 fold down regulated in diseased samples compared to healthy tissue.

<p>Table 1</p>

Significantly regulated miRNAs on Exiqon chips from SAS analysis

Name of miRNAs on chip

miRNA name in rat*

Lsmean animal PKD

Lsmean animal Control

Log Fold Change PKD_Ctrl

-log10(p-value) for log fold change of PKD_Ctrl

hsa-miR-21

rno-miR-21

0.80

0.24

0.56

4.50

hsa-miR-302c-star

-0.63

-0.33

-0.30

3.32

hsa-miR-31

rno-mir-31

-0.47

-0.13

-0.34

3.22

hsa-miR-302c

-0.76

-0.30

-0.46

3.22

hsa-miR-217

rno-mir-217

-0.74

-0.41

-0.33

3.09

mmu-miR-34b

rno-mir-34b

-0.59

-0.35

-0.24

3.00

hsa-miR-126-star

rno-mir-126-star

-0.32

-0.07

-0.25

2.98

hsa-miR-7

rno-mir-7

-0.60

-0.23

-0.37

2.92

hsa-miR-128b

rno-mir-128

-0.69

-0.37

-0.32

2.92

hsa-miR-302b-star

-0.53

-0.27

-0.26

2.76

hsa-miR-136

rno-mir-136

-0.70

-0.37

-0.33

2.75

hsa-miR-99a

rno-mir-99a

-0.40

-0.14

-0.26

2.68

hsa-miR-448

rno-mir-448

-0.55

-0.27

-0.28

2.64

mmu-miR-380-3p

rno-mir-380

-0.63

-0.12

-0.51

2.62

hsa-miR-20

rno-mir-20

-0.31

-0.12

-0.19

2.58

hsa-miR-96

rno-mir-96

-0.65

-0.40

-0.26

2.57

hsa-miR-372

-0.75

-0.46

-0.29

2.55

mmu-miR-7b

rno-mir-7b

-0.46

-0.13

-0.34

2.48

hsa-miR-379

rno-mir-379

-0.74

-0.40

-0.34

2.47

hsa-miR-203

rno-mir-203

-0.50

-0.23

-0.27

2.34

hsa-miR-147

rno-mir-147

-0.66

-0.42

-0.23

2.16

hsa-miR-196a

rno-mir-196a

0.13

0.38

-0.25

2.10

hsa-miR-335

rno-mir-335

-0.72

-0.21

-0.51

1.94

hsa-miR-216

rno-mir-216

-0.70

-0.41

-0.29

1.94

hsa-miR-128a

rno-mir-128

-0.65

-0.32

-0.33

1.92

hsa-miR-30a-3p

rno-mir-30a

-0.15

0.03

-0.18

1.90

hsa-miR-148a

-0.39

-0.27

-0.12

1.85

hsa-miR-181b

rno-mir-181b

-0.35

-0.14

-0.20

1.80

hsa-miR-346

rno-mir-346

-0.69

-0.39

-0.30

1.78

hsa-miR-377

rno-mir-377

-0.58

-0.35

-0.23

1.75

*miRNA probes present on Exiqon chip start with name "hsa-" and "mmu-" as shown in column 1. The miRNAs listed here are conserved in "Rat", shown in column 2.

 <p>Figure 3</p>

Differential expression of miRNA in PKD and control (Ctrl) animals

Differential expression of miRNA in PKD and control (Ctrl) animals. Heatmap was produced using simultaneous clustering of rows and columns of the data matrix using complete linkage algorithm and a euclidean distance metric. Prior to clustering, values were transformed to zero (row-wise) mean and unit (row-wise) variance. The miRNA clustering tree is shown on the left and the sample clustering tree is shown on the top. The samples are clustering broadly into two groups, control (Ctrl) and PKD. The color scale shown at the right illustrates the relative expression level of the indicated miRNA across all samples: red denotes expression > 0 and blue denotes an expression < 0. miRNAs shown here are from miRNA microarrays.

 <p>Figure 4</p>

qPCR analysis of miRNAs in PKD

qPCR analysis of miRNAs in PKD. Expression of 3 miRNAs (miR-21, 31 and 196a) significantly regualted on miRNA microarray was verified using qPCR assays. *** significantly different at P < 0.001.

Microarray analysis of genes involved in PKD

To study the genetic regulation in PKD, we performed gene expression profiling study using Affymetrix chips (RAE230_2) on PKD/Mhm (cy/+) and control, PKD/Mhm (+/+), rats. The arrays were analyzed by SAS Micro-Array Solution version 1.3. A number of 1740 probe sets, according to custom CDF version 8 44, corresponding to 935 genes were found to be significantly regulated at a cut-off (negative log10) of 5.5584 (Additional file 1). Several genes strongly associated with PKD such as Clusterin 5556, Vimentin 56, Timp 56, Bcl2 57, several members of MAPK signaling 58 etc. were strongly differentially regulated in expected orientations, showing the reliability of mRNA expression profiles. Table 2 shows the top 25 significantly up/down-regulated genes according to the negative log10 of p-values.

<p>Additional file 1</p>

Significantly regulated mRNAs. This table shows significantly regulated mRNAs on the Affymetrix chips obtained from SAS analysis.

Click here for file

 <p>Table 2</p>

Top 25 up-regulated and 25 down-regulated genes on Affymetrix chips from SAS analysis

Affymetrix_ID

UniGene ID

Gene_Symbol

Log_fold_change (>0 = up-regulated; <0 = down-regulated)

-log10(p-value) for Estimate of diseased_healthy

1367581_a_at, 1396689_at

Rn.8871

Spp1

2.2450

41.2288

1378015_at

Rn.39658

RGD:1311996

1.9669

35.0162

1367784_a_at

Rn.1780

Clu

3.3779

29.5397

1367913_at

Rn.105938

Cygb

1.4106

28.3857

1381343_at, 1383222_at

Rn.1708

LOC257646

0.8336

22.6443

1386996_at

Rn.103179

RGD:628855

0.7756

22.4535

1388114_at

Rn.103179

Mrlcb

0.7756

22.4535

1388745_at

Rn.54039

RGD:1304636

0.7278

22.2871

1370992_a_at, 1371258_at

Rn.98846

Fga

1.0091

21.9972

1370186_at

Rn.13686

Psmb9

0.9171

21.6556

1398347_at

Rn.16368

RGD:1312008

1.1720

21.2353

1368504_at, 1398816_at

Rn.40177

Lamp1

0.4187

20.6298

1368168_at

Rn.16933

RGD:620889

2.1632

20.4333

1387391_at

Rn.10089

Cdkn1a

0.4408

20.1517

1373204_at

Rn.17071

RGD1310725_predicted

1.1134

18.9746

1369956_at

Rn.19927

RGD:620570

0.5636

18.7804

1385625_at, 1393240_at

Rn.16151

Efemp2

1.0126

18.3754

1368207_at

Rn.24997

Fxyd5

0.7122

17.9030

1371244_at

Rn.2498

RGD:1307758

0.5877

17.6513

1368160_at

Rn.34026

Igfbp1

1.0420

17.1419

1368821_at, 1368822_at, 1371331_at, 1394119_at

Rn.95652

Fstl1

0.7759

17.1139

1389189_at, 1396539_at, 1398294_at

Rn.6401

Actn1

1.4167

16.9389

1367712_at

Rn.25754

Timp1

1.3548

16.9170

1387892_at

Rn.2458

Tubb5

1.0106

16.8147

1367823_at, 1375144_at, 1386940_at, 1388312_at

Rn.10161

Timp2

0.2867

16.7147

1369400_a_at, 1388044_at, 1388063_a_at, 1398320_at

Rn.44844

Pfkfb2

-0.2293

20.3237

1370268_at

Rn.44291

Kcna5

-0.2714

17.3640

1369178_a_at, 1385148_at

Rn.91176

P2rx1

-0.2108

5.5590

1378419_at

Rn.87496

LOC474169

-0.3129

5.5606

1369279_at

Rn.81185

Dhrs9

-0.2163

5.5612

1388051_at

Rn.81026

Slc26a3

-0.3637

5.5618

1368695_at

Rn.11151

C4bp-ps1

-0.2888

5.5684

1369341_a_at

Rn.7033

Acvrinp1

-0.1886

5.5718

1394129_at, 1396858_at

Rn.7033

Acvrip1

-0.1886

5.5718

1369358_a_at

Rn.37430

Hap1

-0.1699

5.5727

1387320_a_at

Rn.89629

RGD:708527

-0.1887

5.5781

1367571_a_at, 1371206_a_at, 1398322_at

Rn.118681

Igf2

-0.1007

5.5784

1371564_at

Rn.103171

RGD:735157

-0.1572

5.5789

1387292_s_at, 1387991_at

Rn.80837

Capn8

-0.2614

5.5793

1369253_at

Rn.90021

Kremen

-0.2313

5.5831

1369240_a_at

Rn.10096

Avpr1b

-0.2056

5.5835

1382417_at

Rn.90967

RGD:1309306

-0.1498

5.5848

1369552_at

Rn.81187

Samsn1

-0.2144

5.5849

1368763_at

Rn.10652

Il3

-0.2808

5.5851

1369444_at

Rn.21402

Cyp19a1

-0.3457

5.5866

1387582_a_at

Rn.81203

Pde7b

-0.2523

5.5870

1375494_a_at, 1387409_x_at

Rn.10263

Nlgn3

-0.1551

5.5897

1377146_at

Rn.18675

RGD:621647

-0.2512

5.5908

1387615_at

Rn.44391

RGD:621843

-0.2146

5.5965

1387065_at, 1395839_at

Rn.37434

Plcd4

-0.2386

5.5978

In order to reveal the functional meaning of differentially regulated genes, we analyzed the biological pathways these genes may be involved in. We used a curated list of 162 gene sets (pathways) (Additional file 2) corresponding to 1335 genes. They had been obtained from KEGG, MSigDB, GO and Biocarta http://www.biocarta.com/ to identify pathways of significantly regulated genes in 484950. Out of 935 significantly regulated genes, only 233 genes were found in this list. These 233 genes were involved in 100 pathways (as shown in Figure 2), which were further categorized into 24 functional groups, based on KEGG terminology (Additional file 3, Figure 5). Over-representation analysis (ORA) examines the genes that meet a selection criterion and determines if there are gene sets which are statistically over-represented. An ORA of these pathways showed that 13 of them were significantly enriched (P < 0.05) in the PKD (cy/+) animals (as shown in Figure 2). Of those, major signal transduction signalling pathways previously described 585960 as involved in various aspects of PKD, such as TGF-β, mTOR signalling pathway, MAPK, calcium signalling pathway, Wnt and JAK/STAT signalling pathways, were regulated.

<p>Additional file 2</p>

Curated pathway list. This table shows the curated pathways obtained from KEGG, Biocarta, MSigDB and GO.

Click here for file

 <p>Additional file 3</p>

Categories of pathways. This table shows the pathway categories based on KEGG annotation for significantly regulated genes on Affymetrix chips.

Click here for file

 <p>Figure 5</p>

Overrepresented miRNA regulatory pathways in PKD

Overrepresented miRNA regulatory pathways in PKD. Fisher's exact test was used to identify significant enrichment for pathway annotations among predicted targets of dysregulated miRNAs and differentially expressed mRNAs in PKD. Pathways (from KEGG, MSigDB, Biocarta, GO) have been grouped in larger functional categories according to the KEGG annotation. The pie-chart shows 22 functional categories and each pie represents a functional category with an overrepresentation of regulatory pathways of miRNA targets as well as mRNAs. Only pathways overlapped from the functional patterns of predicted miRNA targets and differentially expressed mRNAs are shown.

Identifying miRNA-target interaction

Our miRNA-micorarray profiling revealed changes in miRNA expression pattern, indicating that miRNAs play a role in regulating the gene expression during PKD. We mapped the possible targets of these differentially regulated miRNAs to differentially regulated genes (935, obtained from our mRNA expression experiment). We first looked for already reported targets by comparing the list of differentially regulated miRNAs and the genes to the available miRNA-target interactions present in the Argonaute database 45. A total of 25 genes are reported as targets of 15 miRNAs (Table 3a). But none of these miRNA-target interactions were reported in PKD. Out of these 25 genes, 11 genes are known to affect 23 pathways that were grouped into 11 functional categories (Figure 6a). Five pathways, namely GnRH signaling pathway, MAPK signaling pathway, Long term depression, Calcium signaling pathway and Neuroactive ligand receptor interaction were significantly enriched in PKD animals, as revealed by ORA.

<p>Table 3</p>

miRNAs and their targets

a: miRNAs and their previously reported targets (from Argonaute database). miRNAs and their corresponding targets are both differentially regulated during PKD.

miRNA

Target Genes

Pathways

miR-128

ABCB9, BTG1, DSCR1, RASD1

ABC transporters General

miR-136

GRN, PPP1R9B

miR-147

HOXA1, PTGFRN

miR-148

EGR3, SCN3A

miR-181b

IGF1R, NKX6-1

Adherens junction, Maturity onset diabetes of the, Focal adhesion, **Long term depression

miR-196a

ABCB9, CPB2, IRS1, MAPK10

ABC transporters General, Complement and coagulation cas, Adipocytokine signaling pathwa, Insulin signaling pathway, Type II diabetes mellitus, Fc epsilon RI signaling pathwa, Focal adhesion, **GnRH signaling pathway, **MAPK signaling pathway, Toll like receptor signaling p, Wnt signaling pathway

miR-203

SARA1

miR-20

BTG1, SARA1, YWHAB

Cell cycle

miR-21

TPM1

mir-216

GNAZ

**Long term depression

miR-217

RHOA

Adherens junction, Axon guidance, Focal adhesion, Leukocyte transendothelial mig, Regulation of actin cytoskelet, TGF beta signaling pathway, T cell receptor signaling path, Tight junction, Wnt signaling pathway

miR-31

ATP2B2, DNM1L, EGR3, PPP1R9B, YWHAB

**Calcium signaling pathway, Cell cycle

miR-7

SLC23A2

miR-7b

HRH3, NCDN, SLC23A2

**Neuroactive ligand receptor in

b: miRNAs and their targets (from TargetScan and miRanda). miRNAs and their corresponding targets are both differentially regulated during PKD.

miRNA

Target Genes

Pathways

miR-128

ABCB9, BTG2, CACNB2, CNR1, COL3A1, GLRA2, IRS1, NEK6, PDE7B, PTPN5, SV2A, SYT4, YWHAB, NR5A2, NTRK3

ABC transporters General, **MAPK signaling pathway, **Neuroactive ligand receptor in, **Cell Communication, **ECM receptor interaction, Focal adhesion, Adipocytokine signaling pathwa, Insulin signaling pathway, Type II diabetes mellitus, Purine metabolism, Cell cycle, Maturity onset diabetes of the

miR-136

KCNH7

miR-148

OTX1, YWHAB

Cell cycle

miR-181b

ADAMTS1, ATP2B2, CACNB2, CDH13, CNR1, DUSP6, EGR3, EPHA7, GRIK2, GRM5, GRM7, HOXA1, MMP14

**Calcium signaling pathway, **MAPK signaling pathway, **Neuroactive ligand receptor in, Axon guidance, Gap junction, **Long term depression, Long term potentiation, **GnRH signaling pathway

miR-196a

ABCB9, COL3A1, EPHA7, GAS7, OTX1

ABC transporters General, **Cell Communication, **ECM receptor interaction, Focal adhesion, Axon guidance

miR-203

TGFB3

Cell cycle, **MAPK signaling pathway, TGF beta signaling pathway

miR-21

BTG2

miR-217

CLU, FN1, GRIK2, KCNH5, NR4A2, RAP1B

**Cell Communication, **ECM receptor interaction, Focal adhesion, Regulation of actin cytoskelet, **Neuroactive ligand receptor in, Leukocyte transendothelial mig, Long term potentiation, **MAPK signaling pathway

miR-302b*

ATP2B2

**Calcium signaling pathway

miR-302c

ATP2B2, CNR1, SNF1LK

**Calcium signaling pathway, **Neuroactive ligand receptor in

miR-302c*

ATP2B2, SNF1LK

**Calcium signaling pathway

miR-30a-3p

CCKBR, COLEC12, EPHA7, GRM7, JUN, KCNAB1, LIN7A, MAMDC1, PRRX1

**Calcium signaling pathway, **Neuroactive ligand receptor in, Axon guidance, B cell receptor signaling path, Focal adhesion, **GnRH signaling pathway, **MAPK signaling pathway, T cell receptor signaling path, Toll like receptor signaling p, Wnt signaling pathway

miR-346

GRM7, LTBP2

**Neuroactive ligand receptor in

miR-372

ATP2B2, NR4A2, SNF1LK, RET, SLC11A2

**Calcium signaling pathway

miR-448

COLEC12, DNM3, GRIK2, IGF1R, IL12B, KCNH7, KCNIP4, SCN3A, SCN5A

**Neuroactive ligand receptor in, Adherens junction, Focal adhesion, **Long term depression, **Cytokine cytokine receptor int, **Jak STAT signaling pathway, Toll like receptor signaling p, **Type I diabetes mellitus

miR-34b

BTG2, CALCR, DLL1, MYRIP

**Neuroactive ligand receptor in, Notch signaling pathway

miR-380-3p

BCL2L1

Amyotrophic lateral sclerosis, Apoptosis, **Jak STAT signaling pathway, Neurodegenerative Disorders

miR-7b

EGR3

**Significantly overrepresented pathways from ORA

 <p>Figure 6</p>

Overrepresented miRNA regulatory pathways in PKD (for target genes obtained from Argonaute)

Overrepresented miRNA regulatory pathways in PKD (for target genes obtained from Argonaute). 6A. The pie-chart shows overrepresented pathways for the target genes obtained from Argonaute. Each pie denotes an overrepresentation of regulatory pathways of predicted targets of dysregulated miRNA as well as differentially expressed mRNAs in PKD; and also the percentage of genes overrepresented in the pathway. 6B. Similarly here the pie-chart shows overrepresented pathways for the predicted miRNA targets obtained from TargetScan as well as miRanda.

Secondly, we mapped the differentially regulated genes for miRNA targets for the differentially regulated miRNAs using two tools, TargetScan 46 and miRanda 47. Only commonly predicted targets for different miRNAs were taken for further analysis. A number of 65 genes were identified as miRNA targets, common from TargetScan as well as miRanda (Table 3b), out of which 31 genes participate in regulating 33 pathways, which could further be grouped into 13 functional categories (Figure 6b). The intersection of TargetScan and miRanda results gave target genes for 20 miRNAs out of 30 differentially regulated miRNAs. This shows that available prediction tools are not yet fully optimal. Altogether, we obtained 89 target genes differentially expressed on Affymetrix chips (Figure 2). These were associated with 36 pathways, out of which 10 were significantly enriched by ORA (Table 3a and 3b; Figure 2).

miRNAs are generally thought to negatively regulate the expression of their targets by mRNA degradation or by repressing translation 61. So if a given miRNA is down-regulated, the expression of its target is expected to be up-regulated. In light of this mode of miRNA action, we next scrutinized the relationship of the expression patterns of the differentially regulated miRNA and their targets identified in the above exercise. Eleven targets for 11 miRNAs had expression patterns in opposite direction (Table 4), indicating that these relationships may be functional miRNA-target combinations in PKD. We were unable to find a direct, down-regulated target, for miR-21.

<p>Table 4</p>

Selected inverse miRNA-target relation identified

miRNA

Target Genes

Pathways

Identified by

Log fold change miRNA

Log fold change gene

hsa-miR-128a

COL3A1

**Cell Communication, **ECM receptor interaction, Focal adhesion

TargetScan miRanda

-0.32881

1.36067

hsa-miR-128a

YWHAB

Cell cycle

TargetScan miRanda

-0.32881

0.39416

hsa-miR-128b

COL3A1

**Cell Communication, **ECM receptor interaction, Focal adhesion

TargetScan miRanda

-0.32151

1.36067

hsa-miR-128b

YWHAB

Cell cycle

TargetScan miRanda

-0.32151

0.39416

hsa-miR-148a

YWHAB

Cell cycle

TargetScan miRanda

-0.11883

0.39416

hsa-miR-181b

IGF1R

Adherens junction, Focal adhesion, **Long term depression

Argonaute

-0.20269

0.39429

hsa-miR-181b

MMP14

**GnRH signaling pathway

TargetScan miRanda

-0.20269

0.63365

hsa-miR-181b

DUSP6

**MAPK signaling pathway

TargetScan miRanda

-0.20269

0.66781

hsa-miR-181b

GRIK2

**Neuroactive ligand receptor in

TargetScan miRanda

-0.20269

0.54227

hsa-miR-196a

COL3A1

**Cell Communication, **ECM receptor interaction, Focal adhesion

TargetScan miRanda

-0.24597

1.36067

hsa-miR-203

TGFB3

Cell cycle, **MAPK signaling pathway, TGF beta signaling pathway

TargetScan miRanda

-0.26753

0.38630

hsa-miR-20a

YWHAB

Cell cycle

Argonaute

-0.18897

0.39416

hsa-miR-217

RHOA

Adherens junction, Axon guidance, Focal adhesion, Leukocyte transendothelial mig, Regulation of actin cytoskelet, T cell receptor signaling path, TGF beta signaling pathway, Tight junction, Wnt signaling pathway

Argonaute

-0.32869

0.56512

hsa-miR-217

FN1

**Cell Communication, **ECM receptor interaction, Focal adhesion, Regulation of actin cytoskelet

TargetScan miRanda

-0.32869

1.15979

hsa-miR-217

RAP1B

Focal adhesion, Leukocyte transendothelial mig, Long term potentiation, **MAPK signaling pathway

TargetScan miRanda

-0.32869

0.40226

hsa-miR-217

GRIK2

**Neuroactive ligand receptor in

TargetScan miRanda

-0.32869

0.54227

hsa-miR-30a-3p

JUN

B cell receptor signaling path, Focal adhesion, **GnRH signaling pathway, **MAPK signaling pathway, T cell receptor signaling path, Toll like receptor signaling p, Wnt signaling pathway

TargetScan miRanda

-0.18488

0.64628

hsa-miR-31

YWHAB

Cell cycle

Argonaute

-0.33805

0.39416

hsa-miR-448

IGF1R

Adherens junction, Focal adhesion, **Long term depression

TargetScan miRanda

-0.28453

0.39429

hsa-miR-448

GRIK2

**Neuroactive ligand receptor in

TargetScan miRanda

-0.28453

0.54227

Discussion

In the current investigation, we explore the possible involvement of miRNAs in PKD. In a well characterized rat model system (Han:SPRD cy/+ rat model; 39), we used a combinatorial approach involving data mining and microarray analysis, to profile the miRNAs involved in PKD. In parallel to the miRNA expression profiling, we also describe the changes in mRNA transcript patterns in PKD using genome-wide Affymetrix arrays. Whereas, the gene expression arrays e.g. Affymetrix arrays have already established themselves for measuring large-scale differential regulation of mRNAs, microarrays have recently been developed to measure miRNA expression changes accurately 4362. We used arrays based on LNA technology 43. The cluster analysis of the control and PKD miRNA-microarrays showed tight clustering PKD samples (Figure 3). Few studies have appeared showing the use of proteomics based approaches for identifying specific miRNA targets 63646566. Several of these studies also applied mRNA-expression arrays to derive correlations between the protein- and messenger- turndown. Over-expressing miRNAs resulted in repressed targets, both at protein and messenger levels: how much both processes contribute to down-regulation of targets depends on individual miRNA-mRNA pairs 65. These studies show that mRNA profiling are indeed valuable tools for studying mRNA-miRNA interaction, although additional information on fine-tuning of proteome-expression may be obtained by including proteomics approaches.

Our study, profiling the changes in the mRNA transcripts in PKD, revealed large-scale changes. Although some transcription factors, such as SP1 67, JUN and c-myc 68 have been implicated to play a role in PKD, the magnitude of transcriptional changes (>900 genes) suggest involvement of other regulators. Moreover, the regulatory basis of changes in the expression of transcription factors involved in PKD remains poorly understood. On the other hand, miRNAs have emerged recently as key regulators of gene expression in many developmental 6970 and disease events 7172. Our miRNA study shows that changes in gene expression during PKD also involve miRNAs.

When we compared the mRNA and miRNA profiles, differentially regulated in PKD, with Argonaute (a comprehensive database on miRNAs; 4571), there were few genes reported as miRNA target like tropomyosin 1, alpha (TPM1) as a target of miR-21, the beta polypeptide of tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein (YWHAB), regulatory subunit 9B of protein phosphatase 1 (PPP1R9B), early growth response 3 (EGR3) and dynamin 1-like (DNM1L) as targets of miR-31, plysia ras-related homolog A2 (RHOA) as targets of miR-217, etc. (Table 3a). But none of these genes had previously been associated with PKD. Over-representation analysis showed the enrichment of five pathways namely, GnRH signaling pathway, MAPK signaling pathway, Long term depression, Calcium signaling pathway and Neuroactive ligand receptor interaction. The comparison of differentially regulated genes/miRNAs to Argonaute database indicates that previously known miRNA-target interactions (Table 3a) could play important roles in PKD.

Parallel profiling of the transcripts as well as miRNAs on the same set of samples gives us insight into potential interactions between miRNAs and differentially expressed targets in PKD. This parallel profiling allowed us to scrutinize for the negative expression patterns for the miRNA-target relation at a given time point (Table 4). A negative relationship of the expression patterns between miRNA and its target mRNA is an important parameter for determining their interactions because miRNA, in general, are regarded as negative regulators of their targets.

Microarray analysis of miRNAs revealed down regulation of 29 out of 30 differentially regulated miRNAs, which corresponded to increased expression of several genes related to pathways upregulated during PKD. To further uncover the functional correlation between differentially expressed mRNAs and miRNAs, we determined functionally related gene sets, or pathways. The differentially regulated mRNAs were associated with 24 functional categories, which included several enriched pathways important to renal diseases. Previous studies of cystic kidneys implicated several pathways thought to contribute to the pathogenesis of renal cysts' formation like mTOR signalling, MAPK (Mitogen-Activated Protein Kinase) signalling, Wnt signalling, and the TGF-β (Transforming Growth Factor-β) pathway.

MAPKs play important roles in the cell by transmitting extracellular signals from the cell membrane to the nucleus 73. MAPKs are activated by various stimuli, influencing cell proliferation, differentiation, and apoptosis. Aberrant regulation of MAPKs and other signalling pathways has been reported to be consistent with altered regulation of cell proliferation and differentiation observed in renal cystic disease 58. Sustained activation of MAPKs in kidney epithelial cells inhibits normal epithelial phenotype and formation of adherens junctions 74. The expression of genes involved in MAPK signalling pathway like MAP3K1, JUN, and MYC was significantly higher in the PKD animals, indicating the activation of MAPK signalling pathway.

Wnt signalling is essential for renal development. Recent research has revealed an unexpected intersection between Wnt signalling and PKD 59. It has been reported that canonical Wnt signalling seemed mandatory for early renal development, but persistent β-catenin signalling seemed to trigger cyst formation at later developmental stages 59. Components of the Wnt signalling pathway like FZD2, JUN, MYC, and RHOA were significantly upregulated in our PKD animals.

TGF-β promotes renal cell hypertrophy and stimulates extracellular matrix accumulation in several renal diseases, including diabetic nephropathy 75 and PKD 76. It activates the inhibitors of the proteases e.g. tissue inhibitors of metalloproteinases and plasminogen activator inhibitor 1 77. TGF-β 1, TGF-β 2 and TGF-β 3 were consistently upregulated in PKD-affected animals. The expression of extracellular matrix components, such as collagen triple helix repeat containing 1 (CTHRC1), and fibronectin 1 (FN1) was significantly higher in animals with PKD. One of the integrins, integrin beta 1 (ITGB1) was upregulated. Therefore, there was a clear activation of the TGF-β signaling pathway in the PKD animals with a significant increase of the synthesis of the extracellular matrix components and inhibition of the proteases that digest this matrix. Recently Kato et al. showed that miRNA miR-192 has been associated with TGF-β pathway in diabetic kidney glomeruli 78. Its implication in PKD has not been shown, though.

We could not find negative co-relations between the predicted targets of the only up-regulated miRNA, miR-21, whose expression was verified by qPCR analysis too. All the predicted targets were up-regulated. It should be noted that alternate action mechanisms for miRNAs also exist. The action of miRNAs may not to be reflected on the level of their target mRNAs as they are believed to block or attenuate further translation of mRNAs to protein. In such conditions, miRNAs will exert their regulatory role on the level of translation. Moreover, a new mode of action where the miRNAs act as positive regulators has also been defined recently 7. Depending upon the state of a cell, a miRNA can act as positive or negative regulator 7.

The specific cellular pathways that were found to be associated with dysregulated miRNAs or differentially expressed transcripts in PKD can be used to shape some initial hypotheses on how alteration of miRNA expression may be directly involved in the disease. Furthermore, the functional correlation between the differentially expressed mRNAs and miRNAs in PKD revealed a tight posttranscriptional regulation network at both mRNA and protein level.

Conclusion

While this work establishes a multi-tiered approach for investigation of miRNA mode of genetic regulations of PKD, the results await further investigation. PKD is an important disease as 8–10% of all patients on renal replacement therapy including haemodialysis or transplantation, suffer from PKD 79. The molecular components have just started to become apparent, and we add another layer of regulators, namely miRNAs. We predict that several of the differentially regulated genes are miRNA targets and miR-21, miR-31, miR-128, miR-147 and miR-217 may be the important players in such interaction. It is interesting to note that miR-31 and miR-217 have not been previously reported in kidney. miR-21 has been reported in kidney 45 but its function has yet not been established. It has been speculated in previous studies that a single miRNA could target more than hundred genes and one gene could be the target of several miRNAs 6180. Knockout and over-expression studies will provide further insight into the regulatory interaction between these miRNAs and their targets in order to properly understand PKD development and design new therapeutic measures.

Authors' contributions

PP carried out the study, analysed and interpreted the data and drafted the manuscript. BB participated in the design of the study and drafting the manuscript. PKS participated in analysis of data. AB helped in animal experiments. SB helped in animal experiments. HJG participated in revising the manuscript critically for important intellectual content. NG designed the study, participated in drafting the manuscript and has given final approval of the version to be published.

Acknowledgements

We thank Dr. Xiaolei Yu for curated pathway lists, Dr. Mirco Castoldi for performing Exiqon miRNA arrays at EMBL, Heidelberg, Germany and Maria Saile for the technical support. This work was supported by the DFG research Training Group 886 'Molecular Imaging Methods for the analysis of Gene and Protein Expression'. There is no kind of conflict of interest for any of the authors of this paper.

 <p>MicroRNAs: small RNAs with a big role in gene regulation</p> He L Hannon GJ Nat Rev Genet 2004 5 522 531 10.1038/nrg1379 15211354 <p>MicroRNAs: a developing story</p> Pasquinelli AE Hunter S Bracht J Curr Opin Genet Dev 2005 15 200 205 10.1016/j.gde.2005.01.002 15797203 <p>Oncomirs – microRNAs with a role in cancer</p> Esquela-Kerscher A Slack FJ Nat Rev Cancer 2006 6 259 269 10.1038/nrc1840 16557279 <p>The functions of animal microRNAs</p> Ambros V Nature 2004 431 350 355 10.1038/nature02871 15372042 <p>Demystifying small RNA pathways</p> Pasquinelli AE Dev Cell 2006 10 419 424 10.1016/j.devcel.2006.03.005 16625708 <p>Molecular biology. The two faces of miRNA</p> Buchan JR Parker R Science 2007 318 1877 1878 10.1126/science.1152623 18096794 <p>Switching from repression to activation: microRNAs can up-regulate translation</p> Vasudevan S Tong Y Steitz JA Science 2007 318 1931 1934 10.1126/science.1149460 18048652 <p>Transcription and processing of human microRNA precursors</p> Cullen BR Mol Cell 2004 16 861 865 10.1016/j.molcel.2004.12.002 15610730 <p>siRNA and miRNA: an insight into RISCs</p> Tang G Trends Biochem Sci 2005 30 106 114 10.1016/j.tibs.2004.12.007 15691656 <p>Dicers at RISC; the mechanism of RNAi</p> Tijsterman M Plasterk RH Cell 2004 117 1 3 10.1016/S0092-8674(04)00293-4 15066275 <p>MicroRNAs act sequentially and asymmetrically to control chemosensory laterality in the nematode</p> Chang S Johnston RJ Jr Frokjaer-Jensen C Lockery S Hobert O Nature 2004 430 785 789 10.1038/nature02752 15306811 <p>A microRNA controlling left/right neuronal asymmetry in Caenorhabditis elegans</p> Johnston RJ Hobert O Nature 2003 426 845 849 10.1038/nature02255 14685240 <p>The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14</p> Lee RC Feinbaum RL Ambros V Cell 1993 75 843 854 10.1016/0092-8674(93)90529-Y 8252621 <p>The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans</p> Reinhart BJ Slack FJ Basson M Pasquinelli AE Bettinger JC Rougvie AE Horvitz HR Ruvkun G Nature 2000 403 901 906 10.1038/35002607 10706289 <p>bantam encodes a developmentally regulated microRNA that controls cell proliferation and regulates the proapoptotic gene hid in Drosophila</p> Brennecke J Hipfner DR Stark A Russell RB Cohen SM Cell 2003 113 25 36 10.1016/S0092-8674(03)00231-9 12679032 <p>The Drosophila microRNA Mir-14 suppresses cell death and is required for normal fat metabolism</p> Xu P Vernooy SY Guo M Hay BA Curr Biol 2003 13 790 795 10.1016/S0960-9822(03)00250-1 12725740 <p>MicroRNAs modulate hematopoietic lineage differentiation</p> Chen CZ Li L Lodish HF Bartel DP Science 2004 303 83 86 10.1126/science.1091903 14657504 <p>MicroRNA biogenesis and cancer</p> Gregory RI Shiekhattar R Cancer Res 2005 65 3509 3512 10.1158/0008-5472.CAN-05-0298 15867338 <p>A microRNA polycistron as a potential human oncogene</p> He L Thomson JM Hemann MT Hernando-Monge E Mu D Goodson S Powers S Cordon-Cardo C Lowe SW Hannon GJ Hammond SM Nature 2005 435 828 833 10.1038/nature03552 15944707 <p>MicroRNA expression profiles classify human cancers</p> Lu J Getz G Miska EA varez-Saavedra E Lamb J Peck D Sweet-Cordero A Ebert BL Mak RH Ferrando AA Downing JR Jacks T Horvitz HR Golub TR Nature 2005 435 834 838 10.1038/nature03702 15944708 <p>MicroRNAs and cancer</p> McManus MT Semin Cancer Biol 2003 13 253 258 10.1016/S1044-579X(03)00038-5 14563119 <p>Nephronophthisis-associated ciliopathies</p> Hildebrandt F Zhou W J Am Soc Nephrol 2007 18 1855 1871 10.1681/ASN.2006121344 17513324 <p>NEK8 mutations affect ciliary and centrosomal localization and may cause nephronophthisis</p> Otto EA Trapp ML Schultheiss UT Helou J Quarmby LM Hildebrandt F J Am Soc Nephrol 2008 19 587 592 10.1681/ASN.2007040490 18199800 <p>Piecing together a ciliome</p> Inglis PN Boroevich KA Leroux MR Trends Genet 2006 22 491 500 10.1016/j.tig.2006.07.006 16860433 <p>Cilia and centrosomes: a unifying pathogenic concept for cystic kidney disease?</p> Hildebrandt F Otto E Nat Rev Genet 2005 6 928 940 16341073 <p>Cilia-related diseases</p> Afzelius BA J Pathol 2004 204 470 477 10.1002/path.1652 15495266 <p>An incredible decade for the primary cilium: a look at a once-forgotten organelle</p> Davenport JR Yoder BK Am J Physiol Renal Physiol 2005 289 F1159 F1169 10.1152/ajprenal.00118.2005 16275743 <p>Loss of BBS proteins causes anosmia in humans and defects in olfactory cilia structure and function in the mouse</p> Kulaga HM Leitch CC Eichers ER Badano JL Lesemann A Hoskins BE Lupski JR Beales PL Reed RR Katsanis N Nat Genet 2004 36 994 998 10.1038/ng1418 15322545 <p>Polycystic kidney disease prevented by transgenic RNA interference</p> Bouillet P Robati M Bath M Strasser A Cell Death Differ 2005 12 831 833 10.1038/sj.cdd.4401603 15818405 <p>Genetics and pathogenesis of polycystic kidney disease</p> Igarashi P Somlo S J Am Soc Nephrol 2002 13 2384 2398 10.1097/01.ASN.0000028643.17901.42 12191984 <p>Apoptosis and loss of renal tissue in polycystic kidney diseases</p> Woo D N Engl J Med 1995 333 18 25 10.1056/NEJM199507063330104 7776989 <p>Mechanisms and genes of cellular suicide</p> Steller H Science 1995 267 1445 1449 10.1126/science.7878463 7878463 <p>Bcl-2-deficient mice demonstrate fulminant lymphoid apoptosis, polycystic kidneys, and hypopigmented hair</p> Veis DJ Sorenson CM Shutter JR Korsmeyer SJ Cell 1993 75 229 240 10.1016/0092-8674(93)80065-M 8402909 <p>When cilia go bad: cilia defects and ciliopathies</p> Fliegauf M Benzing T Omran H Nat Rev Mol Cell Biol 2007 8 880 893 10.1038/nrm2278 17955020 <p>Mutations in a novel gene, NPHP3, cause adolescent nephronophthisis, tapeto-retinal degeneration and hepatic fibrosis</p> Olbrich H Fliegauf M Hoefele J Kispert A Otto E Volz A Wolf MT Sasmaz G Trauer U Reinhardt R Sudbrak R Antiqnac C Gretz N Walz G Schermer B Benzing T Hildebrandt F Omran H Nat Genet 2003 34 455 459 10.1038/ng1216 12872122 <p>Extracellular signal-regulated kinase inhibition slows disease progression in mice with polycystic kidney disease</p> Omori S Hida M Fujita H Takahashi H Tanimura S Kohno M Awazu M J Am Soc Nephrol 2006 17 1604 1614 10.1681/ASN.2004090800 16641154 <p>Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease</p> Tao Y Kim J Schrier RW Edelstein CL J Am Soc Nephrol 2005 16 46 51 10.1681/ASN.2004080660 15563559 <p>A new rat model for polycystic kidney disease of humans</p> Kaspareit-Rittinghausen J Deerberg F Rapp KG Wcislo A Transplant Proc 1990 22 2582 2583 2264162 <p>Rat models of autosomal dominant polycystic kidney disease</p> Gretz N Kranzlin B Pey R Schieren G Bach J Obermuller N Ceccherini I Kloting I Rohmeiss P Bachmann S Hafner M Nephrol Dial Transplant 1996 11 Suppl 6 46 51 9044328 <p>Missense mutation in sterile alpha motif of novel protein SamCystin is associated with polycystic kidney disease in (cy/+) rat</p> Brown JH Bihoreau MT Hoffmann S Kranzlin B Tychinskaya I Obermuller N Podlich D Boehn SN Kaisaki PJ Megel N Danoy P Copley RR Broxholme J Witzgall R Lathrop M Gretz N Gaugier D J Am Soc Nephrol 2005 16 3517 3526 10.1681/ASN.2005060601 16207829 <p>Characterization of a major modifier locus for polycystic kidney disease (Modpkdr1) in the Han:SPRD(cy/+) rat in a region conserved with a mouse modifier locus for Alport syndrome</p> Bihoreau MT Megel N Brown JH Kranzlin B Crombez L Tychinskaya Y Broxholme J Kratz S Bergmann V Hoffmann S Gauguier D Gretz N Hum Mol Genet 2002 11 2165 2173 10.1093/hmg/11.18.2165 12189169 <p>Gender-dependent disease severity in autosomal polycystic kidney disease of rats</p> Gretz N Ceccherini I Kranzlin B Kloting I Devoto M Rohmeiss P Hocher B Waldherr R Romeo G Kidney Int 1995 48 496 500 10.1038/ki.1995.319 7564118 <p>A sensitive array for microRNA expression profiling (miChip) based on locked nucleic acids (LNA)</p> Castoldi M Schmidt S Benes V Noerholm M Kulozik AE Hentze MW Muckenthaler MU RNA 2006 12 913 920 1440900 16540696 10.1261/rna.2332406 <p>Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data</p> Dai M Wang P Boyd AD Kostov G Athey B Jones EG Bunney WE Myers RM Speed TP Akil H Watson SJ Meng F Nucleic Acids Res 2005 33 e175 1283542 16284200 10.1093/nar/gni179 <p>Argonaute – a database for gene regulation by mammalian microRNAs</p> Shahi P Loukianiouk S Bohne-Lang A Kenzelmann M Kuffer S Maertens S Eils R Grone HJ Gretz N Brors B Nucleic Acids Res 2006 34 D115 D118 1347455 16381827 10.1093/nar/gkj093 <p>Prediction of mammalian microRNA targets</p> Lewis BP Shih IH Jones-Rhoades MW Bartel DP Burge CB Cell 2003 115 787 798 10.1016/S0092-8674(03)01018-3 14697198 <p>Human MicroRNA targets</p> John B Enright AJ Aravin A Tuschl T Sander C Marks DS PLoS Biol 2004 2 e363 521178 15502875 10.1371/journal.pbio.0020363 <p>Using the KEGG database resource</p> Aoki KF Kanehisa M Curr Protoc Bioinformatics 2005 Chapter 1 Unit 18428742 <p>The Gene Ontology (GO) database and informatics resource</p> Harris MA Clark J Ireland A Lomax J Ashburner M Foulger R Eilbeck K Lewis S Marshall B Mungall C Richter J Rubin GM Blake JA Bult C Dolan M Drabkin H Eppig JT Hill DP Ni L Ringwald M Balakrishnan R Cherry JM Christie KR Costanzo MC Dwight SS Engel S Fisk DG Hirschman JE Hong EL Nash RS Sethuraman A Theesfeld CL Botstein D Dolinski K Feierbach B Berardini T Mundodi S Rhee SY Apweiler R Barrell D Camon E Dimmer E Lee V Chisholm R Gaudet P Kibbe W Kishore R Schwarz EM Sternberg P Gwinn M Hannick L Wortman J Berriman M Wood V de la Cruz N Tonellato P Jaiswal P Seigfried T White R Nucleic Acids Res 2004 32 D258 D261 308770 14681407 10.1093/nar/gkh066 <p>GSEA-P: a desktop application for Gene Set Enrichment Analysis</p> Subramanian A Kuehn H Gould J Tamayo P Mesirov JP Bioinformatics 2007 23 3251 3253 10.1093/bioinformatics/btm369 17644558 <p>Group testing for pathway analysis improves comparability of different microarray datasets</p> Manoli T Gretz N Grone HJ Kenzelmann M Eils R Brors B Bioinformatics 2006 22 2500 2506 10.1093/bioinformatics/btl424 16895928 <p>Identification of differentially expressed microRNAs by microarray: a possible role for microRNA genes in pituitary adenomas</p> Bottoni A Zatelli MC Ferracin M Tagliati F Piccin D Vignali C Calin GA Negrini M Croce CM Degli Uberti EC J Cell Physiol 2007 210 370 377 10.1002/jcp.20832 17111382 <p>Normalization of microRNA expression levels in quantitative RT-PCR assays: identification of suitable reference RNA targets in normal and cancerous human solid tissues</p> Peltier HJ Latham GJ RNA 2008 14 844 852 2327352 18375788 10.1261/rna.939908 <p>Phylogenetic shadowing and computational identification of human microRNA genes</p> Berezikov E Guryev V van de BJ Wienholds E Plasterk RH Cuppen E Cell 2005 120 21 24 10.1016/j.cell.2004.12.031 15652478 <p>New insights into the molecular pathophysiology of polycystic kidney disease</p> Murcia NS Sweeney WE Jr Avner ED Kidney Int 1999 55 1187 1197 10.1046/j.1523-1755.1999.00370.x 10200981 <p>The etiology, pathogenesis, and treatment of autosomal dominant polycystic kidney disease: recent advances</p> Grantham JJ Am J Kidney Dis 1996 28 788 803 10.1016/S0272-6386(96)90378-9 8957030 <p>Dysregulation of cellular proliferation and apoptosis mediates human autosomal dominant polycystic kidney disease (ADPKD)</p> Lanoix J D'Agati V Szabolcs M Trudel M Oncogene 1996 13 1153 1160 8808689 <p>Sustained activation of MAPK/ERKs signaling pathway in cystic kidneys from bcl-2 -/- mice</p> Sorenson CM Sheibani N Am J Physiol Renal Physiol 2002 283 F1085 F1090 12372784 <p>Wnt signaling in polycystic kidney disease</p> Benzing T Simons M Walz G J Am Soc Nephrol 2007 18 1389 1398 10.1681/ASN.2006121355 17429050 <p>The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease</p> Shillingford JM Murcia NS Larson CH Low SH Hedgepeth R Brown N Flask CA Novick AC Goldfarb DA Kramer-Zucker A Walz G Piontek KB Germino GG Weimbs T Proc Natl Acad Sci USA 2006 103 5466 5471 1459378 16567633 10.1073/pnas.0509694103 <p>How do microRNAs regulate gene expression?</p> Jackson RJ Standart N Sci STKE 2007 2007 re1 10.1126/stke.3672007re1 17200520 <p>MicroRNA-155 is induced during the macrophage inflammatory response</p> O'Connell RM Taganov KD Boldin MP Cheng G Baltimore D Proc Natl Acad Sci USA 2007 104 1604 1609 1780072 17242365 10.1073/pnas.0610731104 <p>Identification of miRNA targets with stable isotope labeling by amino acids in cell culture</p> Vinther J Hedegaard MM Gardner PP Andersen JS Arctander P Nucleic Acids Res 2006 34 e107 1636363 16945957 10.1093/nar/gkl590 <p>MicroRNA-target pairs in the rat kidney identified by microRNA microarray, proteomic, and bioinformatic analysis</p> Tian Z Greene AS Pietrusz JL Matus IR Liang M Genome Res 2008 18 404 411 2259104 18230805 10.1101/gr.6587008 <p>Widespread changes in protein synthesis induced by microRNAs</p> Selbach M Schwanhausser B Thierfelder N Fang Z Khanin R Rajewsky N Nature 2008 455 58 63 10.1038/nature07228 18668040 <p>The impact of microRNAs on protein output</p> Baek D Villen J Shin C Camargo FD Gygi SP Bartel DP Nature 2008 455 64 71 10.1038/nature07242 18668037 <p>Common regulatory elements in the polycystic kidney disease 1 and 2 promoter regions</p> Lantinga-van LI Leonhard WN Dauwerse H Baelde HJ van Oost BA Breuning MH Peters DJ Eur J Hum Genet 2005 13 649 659 10.1038/sj.ejhg.5201392 15770226 <p>Perinatal lethality with kidney and pancreas defects in mice with a targetted Pkd1 mutation</p> Lu W Peissel B Babakhanlou H Pavlova A Geng L Fan X Larson C Brent G Zhou J Nat Genet 1997 17 179 181 10.1038/ng1097-179 9326937 <p>MicroRNAs in the search for understanding human diseases</p> Perera RJ Ray A BioDrugs 2007 21 97 104 10.2165/00063030-200721020-00004 17402793 <p>miR-150, a microRNA expressed in mature B and T cells, blocks early B cell development when expressed prematurely</p> Zhou B Wang S Mayr C Bartel DP Lodish HF Proc Natl Acad Sci USA 2007 104 7080 7085 1855395 17438277 10.1073/pnas.0702409104 <p>MicroRNAs in normal and cancer cells: a new class of gene expression regulators</p> Bagnyukova TV Pogribny IP Chekhun VF Exp Oncol 2006 28 263 269 17285108 <p>Impaired microRNA processing enhances cellular transformation and tumorigenesis</p> Kumar MS Lu J Mercer KL Golub TR Jacks T Nat Genet 2007 39 673 677 10.1038/ng2003 17401365 <p>Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation</p> Marshall CJ Cell 1995 80 179 185 10.1016/0092-8674(95)90401-8 7834738 <p>Differential modulation of cadherin-mediated cell-cell adhesion by platelet endothelial cell adhesion molecule-1 isoforms through activation of extracellular regulated kinases</p> Sheibani N Sorenson CM Frazier WA Mol Biol Cell 2000 11 2793 2802 14956 10930470 <p>Diabetic nephropathy and transforming growth factor-beta: transforming our view of glomerulosclerosis and fibrosis build-up</p> Chen S Jim B Ziyadeh FN Semin Nephrol 2003 23 532 543 10.1053/S0270-9295(03)00132-3 14631561 <p>A possible role for metalloproteinases in renal cyst development</p> Obermuller N Morente N Kranzlin B Gretz N Witzgall R Am J Physiol Renal Physiol 2001 280 F540 F550 11181417 <p>Role of transforming growth factor-beta in diabetic glomerulosclerosis and renal hypertrophy</p> Ziyadeh FN Sharma K Kidney Int Suppl 1995 51 S34 S36 7474686 <p>MicroRNA-192 in diabetic kidney glomeruli and its function in TGF-beta-induced collagen expression via inhibition of E-box repressors</p> Kato M Zhang J Wang M Lanting L Yuan H Rossi JJ Natarajan R Proc Natl Acad Sci USA 2007 104 3432 3437 1805579 17360662 10.1073/pnas.0611192104 <p>Molecular genetics of polycystic kidney disease</p> Calvet JP J Nephrol 1998 11 24 34 9561482 <p>Dynamic regulation of miRNA expression in ordered stages of cellular development</p> Neilson JR Zheng GX Burge CB Sharp PA Genes Dev 2007 21 578 589 1820899 17344418 10.1101/gad.1522907